Gabriela Ecco

Gabriela joined +ND Capital in our Lausanne office in 2021 and is currently a board observer of EVIR Therapeutics, Vandria and Osasuna Therapeutics. She is also a board observer of AIRNA and a former board observer of Cellpoint (sold to Galapagos).

Prior to this, Gabriela has accumulated 15 years of experience in R&D in academia and industry. She has contributed to different areas of life sciences, including molecular and structural biology, infectious diseases, embryonic stem cells biology, tissue engineering, epigenetics, bioinformatics, and cancer molecular diagnostics. During her career, Gabriela has authored several high-impact peer-reviewed scientific publications and has led the development of different products for molecular diagnostics in oncology. Gabriela is passionate about science and innovation and her motivation is to help bring to the market new technologies that can change people’s lives.

Gabriela holds a PhD in Biotechnology and Bioengineering from EPFL and a Certificate of Advanced Studies (CAS) in Management of Biotech, Medtech and Pharma Ventures from EPFL.